PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Cancer Research UK teams up with Teon on new cancer drug

Cancer Research UK (CRUK) has signed a collaboration agreement with Teon Therapeutics to advance early clinical development of the latter’s new cancer drug.
The focus of the agreement is Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist, TT-702.
Under the terms of the agreement, CRUK will sponsor the first-in-human Phase I/II clinical development of TT-702. This will be led by a team at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
The Centre for Drug Development, Teon and a team of clinical investigators led by Professor Johann de Bono are currently preparing to launch the early clinical trial in the second half of 2021.
“We are delighted to be working with Teon to advance TT-702 into human trials, and the drug makes an exciting addition to our growing portfolio of innovative anti-cancer agents,” said Nigel Blackburn, director of drug development, CRUK.
“Finding new ways to target difficult-to-treat cancers remains a research priority for Cancer Research UK, and despite the challenges from the COVID-19 pandemic, we are continuing to leverage new partnerships like Teon, so we can bring potentially life-saving treatments closer to patients who need them,” he added.
TT-702 is an adenosine receptor that specifically targets the A2B receptor, which is overexpressed on certain types of tumour cells and immune cells.
In the tumour microenvironment, high levels of adenosine activate the A2B receptor, which in turn triggers tumour cell growth and the suppression of T-cells, which allows cancer cells to avoid immune detection.
TT-702 is designed to prevent the A2B receptor from being activated by high levels of adenosine, which prevents cancer cell growth and bolsters the anti-tumour immune response.
The early-stage study will test the safety and efficacy of TT-702 in multiple cancer indications, including hard-to-treat prostate cancer and triple-negative breast cancer.
The drug will be evaluated as both a monotherapy and in combination with anti-PD-1 immunotherapy or hormonal therapy.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026